A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib

A Phase 2, Multicenter, Double-Blind, Parallel Group Long Term Extension Study in Rheumatoid Arthritis Subjects Who Have Completed a Preceding Phase 2 Randomized Controlled Trial With ABBV-105 Given Alone or in Combination With Upadacitinib (ABBV-599)

This was a long-term extension (LTE) study to assess the safety, tolerability, and efficacy of ABBV-105 (elsubrutinib [ELS]) and ABBV-599 (ELS 60 mg and upadacitinib [UPA] 15 mg) in participants with rheumatoid arthritis (RA) who completed Study M16-063 (NCT03682705).

Study Overview

• Status: Terminated
• Conditions: Rheumatoid Arthritis (RA)
• Intervention / Treatment: Drug: Placebo for elsubrutinib; Drug: Elsubrutinib; Drug: Upadacitinib; Drug: Placebo for upadacitinib

Detailed Description

This was a Phase 2, double-blind, multicenter, long-term extension (LTE) study to assess the safety, tolerability, and efficacy of 3 doses of ABBV-105 (elsubrutinib [ELS] 5 mg, 20 mg, and 60 mg) and ABBV-599 (ELS 60 mg and upadacitinib [UPA] 15 mg) in adults with active rheumatoid arthritis with inadequate response or intolerance to biologic disease-modifying antirheumatic drugs (bDMARDs). Participants who successfully completed treatment in the feeder Study M16-063, a Phase 2 dose exploratory study, were eligible to participate in this study. Those who met eligibility criteria and entered this study receiving ELS, ABBV-599, or UPA from Study M16-063 continued on their previously assigned treatment through termination of this study. Participants originally randomized to placebo in Study M16-063 rolled over to ABBV-599 in a blinded fashion in this study.

• Study Type: Interventional
• Enrollment (Actual): 97
• Phase: Phase 2

Contacts and Locations

Study Locations

• Belgium
  • Leuven, Belgium, 3000
    • UZ Leuven /ID# 207722
  • Bruxelles-Capitale
    • Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium, 1200
      • Cliniques Universitaires Saint Luc /ID# 207719
• Canada
  • Alberta
    • Edmonton, Alberta, Canada, T5M 0H4
      • Rheumatology Research Assoc /ID# 207769
  • Manitoba
    • Winnipeg, Manitoba, Canada, R3A 1M3
      • Manitoba Clinic /ID# 206852
    • Winnipeg, Manitoba, Canada, R3N 0K6
      • CIADS Research Co Ltd /ID# 206853
  • Ontario
    • Toronto, Ontario, Canada, M5G 1X5
      • Mount Sinai Hosp.-Toronto /ID# 206851
  • Saskatchewan
    • Saskatoon, Saskatchewan, Canada, S7K 3H3
      • Dr. Latha Naik /ID# 213440
• Czechia
  • Ostrava, Czechia, 702 00
    • Revmatologie MUDr. Klara Sirova /ID# 209944
  • Pardubice, Czechia, 530 02
    • CCR Czech a.s /ID# 209942
  • Jihlava
    • Jihlava 1, Jihlava, Czechia, 586 01
      • Revmatolog s.r.o. /ID# 209941
  • Praha 2
    • Prague 2, Praha 2, Czechia, 128 00
      • Revmatologicky ustav Praha /ID# 209943
• Hungary
  • Budapest, Hungary, 1027
    • Revita Reumatologiai Rendelo /ID# 208187
  • Szekesfehervar, Hungary, 8000
    • CMED Rehabilitacios es Diagnosztikai Kozpont /ID# 208188
  • Veszprem, Hungary, 8200
    • Vital Medical Center Orvosi-es Fogaszati Kozpont /ID# 208185
  • Borsod-Abauj-Zemplen
    • Miskolc, Borsod-Abauj-Zemplen, Hungary, 3529
      • CRU Hungary Egeszsegugyi és Szolgaltato Kft. /ID# 208186
  • Szabolcs-Szatmar-Bereg
    • Nyíregyháza, Szabolcs-Szatmar-Bereg, Hungary, 4400
      • Szabolcs-Szatmar-Bereg Megyei Korhazak & Egyetemi Oktatokorhaz /ID# 208184
• Poland
  • Warsaw, Poland, 02-691
    • Reumatika - Centrum Reumatologii NZOZ /ID# 209903
  • Malopolskie
    • Cracow, Malopolskie, Poland, 30-149
      • Malopolskie Centrum Kliniczne /ID# 209902
  • Mazowieckie
    • Grodzisk Mazowiecki, Mazowieckie, Poland, 05-825
      • McBk Sc /Id# 212577
    • Warsaw, Mazowieckie, Poland, 00-465
      • NBR Polska /ID# 209904
  • Podlaskie
    • Białystok, Podlaskie, Poland, 15-879
      • ClinicMed Daniluk, Nowak Sp.j. /ID# 212578
• Spain
  • Barcelona, Spain, 08036
    • Hospital Clinic /ID# 207740
  • Bilbao, Spain, 48013
    • Hospital Universitario Basurto /ID# 207737
  • Granada, Spain, 18014
    • Hospital Universitario Virgen de las Nieves /ID# 209975
  • Madrid, Spain, 28040
    • Hospital Clinico Universitario San Carlos /ID# 207738
  • Valencia, Spain, 46026
    • Hospital Universitario y Politecnico La Fe /ID# 207739
  • A Coruna
    • A Coruña, A Coruna, Spain, 15006
      • Hospital Universitario A Coruña - CHUAC /ID# 207732
  • Cantabria
    • Santander, Cantabria, Spain, 39008
      • Hospital Unversitario Marques de Valdecilla /ID# 207729
  • Malaga
    • Málaga, Malaga, Spain, 29010
      • Hospital Regional de Malaga /ID# 207735
• United Kingdom
  • Oxford, United Kingdom, OX3 7LF
    • University of Oxford /ID# 210571

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Participant has completed Study M16-063
• Participant has not developed any laboratory or clinical discontinuation criteria as defined in the Study M16-063 protocol
• Participant is willing and/or able to comply with procedures required in the current study protocol

Exclusion Criteria:

• Participant is currently enrolled or planning to enroll in another interventional clinical study while participating in this study (except the preceding study M16-063)
• Participant requires vaccination with any live vaccine during study participation, including at least 30 days after the last dose of study drug

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: ABBV-599 in M16-063/ABBV-599 in M16-763; 60 mg elsubrutinib capsule once a day by mouth for 48 weeks; 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks	Drug: Elsubrutinib; Elsubrutinib capsule will be administered orally.; Other Names: ABBV-105; Drug: Upadacitinib; Upadacitinib tablet will be administered orally.; Other Names: ABT-494
Experimental: ABBV-105 60 mg/UPA placebo; 60 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks	Drug: Elsubrutinib; Elsubrutinib capsule will be administered orally.; Other Names: ABBV-105; Drug: Placebo for upadacitinib; Upadacitinib placebo tablet will be administered orally.
Experimental: ABBV-105 20 mg/UPA placebo; 20 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks	Drug: Elsubrutinib; Elsubrutinib capsule will be administered orally.; Other Names: ABBV-105; Drug: Placebo for upadacitinib; Upadacitinib placebo tablet will be administered orally.
Experimental: ABBV-105 5 mg/UPA placebo; 5 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks	Drug: Elsubrutinib; Elsubrutinib capsule will be administered orally.; Other Names: ABBV-105; Drug: Placebo for upadacitinib; Upadacitinib placebo tablet will be administered orally.
Experimental: UPA 15 mg/ABBV-105 placebo; 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks; placebo capsule for elsubrutinib once a day by mouth for 48 weeks	Drug: Placebo for elsubrutinib; Placebo capsule for elsubrutinib will be administered orally.; Drug: Upadacitinib; Upadacitinib tablet will be administered orally.; Other Names: ABT-494
Experimental: Placebo in M16-063/ABBV-599 in M16-763; Placebo in M16-063; 60 mg elsubrutinib capsule once a day by mouth for 48 weeks and 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks in M16-763	Drug: Elsubrutinib; Elsubrutinib capsule will be administered orally.; Other Names: ABBV-105; Drug: Upadacitinib; Upadacitinib tablet will be administered orally.; Other Names: ABT-494

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With Adverse Events (AEs)	An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug as either having a reasonable possibility or no reasonable possibility. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug.	On or after the first dose of study drug in Study M16-763, and up to 30 days after the last dose of study drug in Study M16-763, up to 52 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Disease Activity Score 28 C-reactive Protein (DAS28-CRP) From Baseline of Study M16-063 at Each Study Visit in Study M16-763	The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from Baseline indicates improvement in disease activity.	Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Percentage of Participants Achieving Low Disease Activity (LDA) Based on Disease Activity Score 28 C-reactive Protein (DAS28-CRP)	The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. Low Disease Activity (LDA) based on DAS28 (CRP) is defined as achieving a DAS28 (CRP) of less than or equal to 3.2.	Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Percentage of Participants Achieving Clinical Remission (CR) Based on Disease Activity Score 28 C-reactive Protein (DAS28-CRP)	The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. Clinical Remission (CR) based on DAS28 (CRP) is defined as achieving a DAS28 (CRP) of less than 2.6.	Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Change in Clinical Disease Activity Index (CDAI) From Baseline of Study M16-063	The CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. A negative change from Baseline indicates improvement in disease activity.	Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Percentage of Participants Achieving Low Disease Activity (LDA) Based on Clinical Disease Activity Index (CDAI) Criteria	The CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. Low Disease Activity (LDA) based on CDAI is defined as achieving a total CDAI score of less than or equal to 10.	Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Percentage of Participants Achieving Clinical Remission (CR) Based on Clinical Disease Activity Index (CDAI) Criteria	The CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. Complete Remission (CR) based on CDAI is defined as achieving a total CDAI score of less than or equal to 2.8.	Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response	Participants who met the following 3 conditions for improvement from baseline of Study M16-063 were classified as meeting the American College of Rheumatology 20% response (ACR20) criteria: ≥ 20% improvement in 68-tender joint count from Baseline of Study M16-063; ≥ 20% improvement in 66-swollen joint count from Baseline of Study M16-063 and; ≥ 20% improvement in at least 3 of the 5 following parameters from Baseline of Study M16-063:Patient's Assessment of Pain (Visual Analog Scale [VAS])Patient's Global Assessment of Disease Activity (PtGA)Physician's Global Assessment of Disease Activity (PhGA)Health Assessment Questionnaire Disability Index (HAQ-DI)High-sensitivity C-reactive protein (hsCRP)	Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response	Participants who met the following 3 conditions for improvement from baseline of Study M16-063 were classified as meeting the American College of Rheumatology 50% response (ACR50) criteria: ≥ 50% improvement in 68-tender joint count from Baseline of Study M16-063; ≥ 50% improvement in 66-swollen joint count from Baseline of Study M16-063 and; ≥ 50% improvement in at least 3 of the 5 following parameters from Baseline of Study M16-063:Patient's Assessment of Pain (Visual Analog Scale [VAS])Patient's Global Assessment of Disease Activity (PtGA)Physician's Global Assessment of Disease Activity (PhGA)Health Assessment Questionnaire Disability Index (HAQ-DI)High-sensitivity C-reactive protein (hsCRP)	Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response	Participants who met the following 3 conditions for improvement from baseline of Study M16-063 were classified as meeting the American College of Rheumatology 70% response (ACR70) criteria: ≥ 70% improvement in 68-tender joint count from Baseline of Study M16-063; ≥ 70% improvement in 66-swollen joint count from Baseline of Study M16-063 and; ≥ 70% improvement in at least 3 of the 5 following parameters from Baseline of Study M16-063:Patient's Assessment of Pain (Visual Analog Scale [VAS])Patient's Global Assessment of Disease Activity (PtGA)Physician's Global Assessment of Disease Activity (PhGA)Health Assessment Questionnaire Disability Index (HAQ-DI)High-sensitivity C-reactive protein (hsCRP)	Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Change in Swollen Joint Count 66 (SJC66) From Baseline of Study M16-063	Sixty-six joints were assessed for swelling by physical examination. Swelling of each joint was classified as present (1) or absent (0), for a total possible score of 0 (0 joints with swelling) to 66 (worst possible score/66 joints with swelling). Negative values indicate improvement from baseline.	Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Change in Tender Joint Count 68 (TJC68) From Baseline of Study M16-063	Sixty-eight joints were assessed for tenderness by physical examination. Pain or tenderness of each joint was classified as present (1) or absent (0), for a total possible score of 0 (0 joints with tenderness) to 68 (worst possible score/68 joints with tenderness). Negative values indicate improvement from baseline.	Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Change in Participant's Assessment of Pain (Visual Analog Scale [VAS]) From Baseline of Study M16-063	Participants rated their pain on a visual analogue scale (VAS) of 0 to 100 (mm), with 0 representing no pain and 100 representing the worst possible pain. Negative values indicate improvement from baseline.	Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Change in Patient's Global Assessment of Disease Activity (PtGA) From Baseline of Study M16-063	Participants rated their disease activity for the past 24 hours using a Patient's Global Assessment of Disease Activity Global visual analogue scale (VAS). The range is 0 to 100 mm, with 0 representing no disease activity and 100 representing severe disease activity. Negative values indicate improvement from baseline.	Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Change in Physician's Global Assessment of Disease Activity (PhGA) From Baseline of Study M16-063	The physician assessed a participant's disease activity at the time of the visit using a Physician's Global Assessment of Disease visual analogue scale (VAS). The range is 0 to 100 mm, with 0 representing no disease activity and 100 representing severe disease activity. Negative values indicate improvement from baseline.	Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Change in Health Assessment Questionnaire Disability Index (HAQ-DI) From Baseline of Study M16-063	The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from baseline in the overall score indicates improvement.	Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Change in High-Sensitivity C-Reactive Protein (Hs-CRP) From Baseline of Study M16-063	C-reactive protein is a blood test marker for inflammation in the body, and levels rise in response to inflammation. A negative change from baseline indicates improvement.	Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Change in Morning Stiffness Severity From Baseline of Study M16-063	Morning stiffness severity was assessed by a numeric rating-scale (NRS). Participants rated the severity of morning stiffness during the past week from 0 to 10 with 0 representing "not severe" and 10 "very severe". Negative values indicate improvement from baseline.	Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763

Collaborators and Investigators

• Sponsor: AbbVie

Publications and helpful links

Helpful Links

• Related Info.

Study record dates

Study Major Dates

• Study Start (Actual): May 13, 2019
• Primary Completion (Actual): September 9, 2020
• Study Completion (Actual): September 9, 2020

Study Registration Dates

• First Submitted: January 8, 2019
• First Submitted That Met QC Criteria: January 29, 2019
• First Posted (Actual): January 30, 2019

Study Record Updates

• Last Update Posted (Actual): September 16, 2021
• Last Update Submitted That Met QC Criteria: August 18, 2021
• Last Verified: August 1, 2021

More Information

Terms related to this study

• Keywords: Upadacitinib; Rheumatoid Arthritis (RA); ABBV-599; ABBV-105; Elsubrutinib; Long-term extension (LTE)
• Additional Relevant MeSH Terms: Immune System Diseases; Autoimmune Diseases; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Arthritis; Arthritis, Rheumatoid; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antirheumatic Agents; Protein Kinase Inhibitors; Janus Kinase Inhibitors; Upadacitinib
• Other Study ID Numbers: M16-763; 2018-002306-31 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Yes
• IPD Plan Description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
• IPD Sharing Time Frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
• IPD Sharing Access Criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
• IPD Sharing Supporting Information Type: Study Protocol; Statistical Analysis Plan (SAP); Clinical Study Report (CSR)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes